Safety, Efficacy, and Pharmacokinetics Study of Tarceva to Treat Advanced Colorectal Cancer

You may be eligible if

• Subjects must fulfill all of the following criteria to be eligible for study entry:
• Signed informed consent
• At least 18 years of age
• Histologically confirmed metastatic colorectal adenocarcinoma of the colon or rectum
• Resected or biopsied primary tumors or metastatic site will serve as the basis for histologic confirmation.
• Measurable disease (defined as at least one dimension \>2 cm \[\>1 cm on spiral CT scans\])
• ECOG performance status of 0 or 1
• Life expectancy \>3 months
• Use of an effective means of contraception in men and in women of childbearing potential
• Ability to comply with study and follow-up procedures